Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reassessing guidelines for heart failure.

Helmut Drexler1, Kai C Wollert

  • 1Chief Cardiovascular Division, Medical University of Hanover, 30625, Germany. drexler.helmut@mh-hannover.de

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RHOT Proteins Link Mitochondrial Motility to Cardiomyocyte Sarcomere Maturation.

Circulation research·2026
Same author

Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.

European heart journal·2026
Same author

Extracellular BRICK1 drives heart repair after myocardial infarction in mice.

Science translational medicine·2026
Same author

Iron regulatory proteins secure iron availability in skeletal muscle to preserve exercise tolerance in heart failure.

Cardiovascular research·2025
Same author

Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapy.

European journal of endocrinology·2025
Same author

Cysteine-rich with EGF-like domains 2 (CRELD2) is an endoplasmic reticulum stress-inducible angiogenic growth factor promoting ischemic heart repair.

Nature cardiovascular research·2024
Same journal

Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Timing Matters: Effects of Early and Late Estrogen Replacement Therapy on Glucose Metabolism and Vascular Reactivity in Ovariectomized Aged Wistar Rats.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Genetic Variants Associated with High Susceptibility of Premature Ischemic Stroke.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
Same journal

Angiotensin-Converting Enzyme and Hypertension: A Systemic Analysis of Various ACE Inhibitors, Their Side Effects, and Bioactive Peptides as a Putative Therapy for Hypertension.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2023
See all related articles

Recent heart failure management advances include ACE inhibitors as first-line treatment. New trials on angiotensin receptor blockers, beta-blockers, and aldosterone blockers are updating clinical guidelines.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure management has seen significant advancements.
  • Risk factor treatment, like for coronary artery disease, can prevent heart failure.
  • Established treatments and emerging therapies are shaping current practice.

Purpose of the Study:

  • To review recent clinical trial results in heart failure management.
  • To discuss the role of various drug classes in treating heart failure.
  • To inform the update of heart failure clinical guidelines.

Main Methods:

  • Review of key clinical trials including those for ACE inhibitors, ARBs, beta-blockers, and aldosterone receptor blockers.
  • Discussion of trial outcomes regarding survival and symptomatic benefits.

Related Experiment Videos

  • Analysis of specific drug data, including candesartan in preserved ejection fraction heart failure and carvedilol vs. metoprolol tartrate.

    • Main Results:

    • Angiotensin-converting enzyme (ACE) inhibitors demonstrate long-term survival and symptomatic benefits, confirming their first-line status.
    • Angiotensin receptor blockers (ARBs) show efficacy, with emerging data for candesartan in specific heart failure types.
    • The COMET trial suggests potential clinical differences among beta-blockers; eplerenone shows promise in post-MI heart failure patients.

    Conclusions:

    • Current evidence supports ACE inhibitors as foundational therapy for heart failure.
    • ARBs, beta-blockers, and aldosterone receptor blockers represent important therapeutic options with evolving roles.
    • These clinical trial findings are actively influencing the revision of heart failure management guidelines.